GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Total Current Liabilities

Cyclerion Therapeutics (Cyclerion Therapeutics) Total Current Liabilities : $1.44 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cyclerion Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $1.44

Cyclerion Therapeutics Total Current Liabilities Historical Data

The historical data trend for Cyclerion Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Total Current Liabilities Chart

Cyclerion Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 18.25 16.95 11.09 7.63 2.09

Cyclerion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.53 4.95 2.34 2.09 1.44

Cyclerion Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cyclerion Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.984+0
+Other Current Liabilities+Current Deferred Liabilities
=0.102+0
=2.09

Cyclerion Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.28+0
+Other Current Liabilities+Current Deferred Liabilities
=0.161+0
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cyclerion Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Total Current Liabilities
Comparable Companies
PYPD CELZ EMMA BTTX JAGX NRSN TTNP CUBT KTRA FNCH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Website
https://www.cyclerion.com
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Executives
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman director C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades director 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson director CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell director C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht director, officer: Chief Executive Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp 10 percent owner 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino officer: Chief Financial Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright officer: Chief Medical Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault officer: Chief Operating Officer CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie officer: President and CSO C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142

Cyclerion Therapeutics (Cyclerion Therapeutics) Headlines

From GuruFocus

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

By GuruFocusNews GuruFocusNews • 06-17-2022

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

By sperokesalga sperokesalga • 03-27-2023

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

By PurpleRose PurpleRose • 08-09-2022

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

By GuruFocusNews GuruFocusNews • 07-08-2022

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

By GuruFocusNews GuruFocusNews • 06-26-2022

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

By GuruFocusNews GuruFocusNews • 07-10-2022

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

By sperokesalga sperokesalga • 03-22-2023

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

By GuruFocusNews GuruFocusNews • 06-22-2022

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

By sperokesalga sperokesalga • 05-11-2023

Cyclerion Announces Reverse Stock Split

By sperokesalga sperokesalga • 05-15-2023